Trial Profile

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC): a Single Center, Single-arm Phase II Study (APICAL-CRC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Sintilimab (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Liver metastases; Rectal cancer
Focus Therapeutic Use
Acronyms APICAL-CR

24 Nov 2024 According to an Innovent Biologics media release, company will present data from this trial in a poster display session at the European Society of Medical Oncology Asia (ESMO Asia) Congress 2024 from Dec 06-08, 2024.
02 Nov 2024 Results of an exploratory analysis of the pathological outcomes data from a prospective phase II trial testing nADT before radical surgery in HRLPC setting published in the World Journal of Urology.
22 Apr 2024 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com